393 related articles for article (PubMed ID: 21481637)
21. [Anti-angiogenesis targeting drugs: a review].
Jia K; Li J
Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
[TBL] [Abstract][Full Text] [Related]
22. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Lohela M; Bry M; Tammela T; Alitalo K
Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain.
Péoch M; Farion R; Hiou A; Le Bas JF; Pasquier B; Rémy C
Anticancer Res; 2002; 22(4):2147-51. PubMed ID: 12174896
[TBL] [Abstract][Full Text] [Related]
24. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
25. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
27. Angiogenesis in embryos and ischemic diseases.
Breier G; Damert A; Plate KH; Risau W
Thromb Haemost; 1997 Jul; 78(1):678-83. PubMed ID: 9198238
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
29. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Al-Dissi AN; Haines DM; Singh B; Kidney BA
Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
[TBL] [Abstract][Full Text] [Related]
31. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
32. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
33. Molecular angiogenic signaling in angiofibromas after embolization: implications for therapy.
Ngan BY; Forte V; Campisi P
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1170-6. PubMed ID: 19015446
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor and the regulation of angiogenesis.
Ferrara N
Recent Prog Horm Res; 2000; 55():15-35; discussion 35-6. PubMed ID: 11036931
[TBL] [Abstract][Full Text] [Related]
35. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
Issa A; Le TX; Shoushtari AN; Shields JD; Swartz MA
Cancer Res; 2009 Jan; 69(1):349-57. PubMed ID: 19118020
[TBL] [Abstract][Full Text] [Related]
37. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic targeting of the angiopoietin-TIE pathway.
Saharinen P; Eklund L; Alitalo K
Nat Rev Drug Discov; 2017 Sep; 16(9):635-661. PubMed ID: 28529319
[TBL] [Abstract][Full Text] [Related]
39. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis and its role in colorectal tumor and metastasis formation.
Ellis LM
Semin Oncol; 2004 Dec; 31(6 Suppl 17):3-9. PubMed ID: 15696024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
